Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus QUADRAMET.
FLUORODOPA F18 vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical